| Project/Area Number |
17K09619
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
Otsuka Mitsuo 札幌医科大学, 医学部, 研究員 (10398323)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 弘毅 札幌医科大学, 医学部, 教授 (60231396)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 特発性肺線維症 / SP-A / 抗線維化薬 / サーファクタント蛋白質A / ニンテダニブ / ピルフェニドン / サーファクタント蛋白質 / 内科 |
|---|
| Outline of Final Research Achievements |
Background: We aim to clarify whether serum SP-A, SP-D, and KL-6 reflect therapeutic outcomes of pirfenidone and nintedanib administration in patients with IPF. Methods: We retrospectively investigated patients with IPF who were initiated on pirfenidone or nintedanib administration between January 2014 and June 2018 at our hospital. Changes in clinical parameters and serum SP-A, SP-D, and KL-6 levels were evaluated. Results: Forty-nine patients were included (pirfenidone, 23; nintedanib, 26). Stable group comprised 32 patients, while progression group comprised 17 patients. In the stable group, changes in SP-A and KL-6 from baseline to 3 and 6 months significantly decreased compared with the progression group. Changes in SP-A and SP-D levels showed significant negative correlations with the change in %FVC and %DLco. Conclusions: Serum SP-A has a potential as a biomarker of therapeutic outcomes of anti-fibrotic drugs.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、間質性肺炎の血清バイオマーカーであるSP-Aが、抗線維化薬の効果予測バイオマーカーになりうることが明らかとなった。実臨床で測定可能であるので臨床応用可能である。
|
